ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 24, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 24, 2010
News
EMA Committee Makes Decisions on Opioids, Follow-on Biologics
By Angie Drakulich
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued on November 19 a summary of its latest meeting.
Novartis to Seek Innovation and Efficiencies
By Erik Greb
On Nov. 17, 2010, Novartis (Basel) disclosed its long-term business strategy, which emphasizes diversification in what the company described as high-growth healthcare segments.
Bayer Announces Restructuring, Increased Focus in Healthcare Business
By Patricia Van Arnum
Bayer (Leverkusen, Germany) announced last week a restructuring program and a strategy to strengthen its focus in research, development, and marketing of new products in its healthcare and crop-sciences businesses as well an interest in expanding its activities in emerging markets.
Week of Nov. 22, 2010: Company and People Notes: Genzyme Sells Business Unit to Sekisui Chemical; Ablexis Names VP of Research; and More.
Genzyme Sells Business Unit to Sekisui Chemical; Ablexis Names VP of Research; and More.
Regulatory Roundup: FDA Issues Statement for Consumers about Antibiotic Use
FDA Issues Statement for Consumers about Antibiotic Use

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here